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Abstract 
Background 
Depression screening in the cardiovascular disease (CVD) care setting is under-performed,  
also because the issue of the optimal screening tools cut-off is still open. We analysed which 
HADS (Hospital Anxiety and Depression Scale) total score cut-off value shows the best 
properties in two groups of 357 Acute Coronary Syndrome (ACS) and 260 Chronic Coronary 
Artery Disease (CAD) hospitalized patients. 
Methods 
A Receiver Operating Characteristics (ROC) curve was plotted for both groups using the 
Montgomery-Asberg Depression Rating Scale (MADRS) as the criterion. Accuracy, positive 
(PPV) and negative (NPV) predictive values were computed for different cut-off scores. 
Results 
The ROC curves confirmed the excellent/very good accuracy of the HADS in both groups, with 
an area under the curve of .911 for the ACS and .893 for the CAD patients. The cut-off of 14 
showed the best compromise between high sensitivity and good specificity in both groups, with 
high negative predicted values (95.5% and 92.4%, respectively). 
Conclusion 
Using a cut-off value of 14, the HADS could be considered a good screening tool to identify 
hospitalized CAD and ACS patients requiring a more accurate depression assessment,  
in order to promptly plan the most appropriate treatment strategies and prevent the negative 
effects of depression in CVD patients. 
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1. Introduction 
A recent systematic analysis of the “Global Burden of Disease Study 2013” underlined once 
again that cardiovascular deaths still account for almost a third of all deaths globally [1].  
There is extensive evidence that cardiovascular disease (CVD) and depression reinforce each 
other, with a downward spiral association [2]. Depression results in an 80–90% increased risk 
of CVD onset [3] and is strongly linked with adverse outcomes, negatively contributing to the 
progression and prognosis of the disease. Furthermore, CVD itself could increase the risk of 
developing depressive disorders [2], with Major Depressive Disorder (MDD) showing a 
prevalence of 20% to 30% in coronary heart disease (CHD) patients [4].  
Although several clinical guidelines recommend early screening and evaluation for treatment of 
depression [5], clinical cardiologists often do not take into account depression as a negative risk 
factor, underestimating its negative effect. What is more, routine screening in the hospital care 
setting is still under-performed, also because of conflicting and confused findings regarding the 
optimal tool [4,6,7]. A recent systematic review analysed the diagnostic accuracy of different 
screening tools, including the “Hospital Anxiety and Depression Scale” (HADS), in detecting 
MDD in CHD patients [4]. Although it highlighted that the HADS is a useful self-report 
instrument in CVD patients [4], other studies call into question the diagnostic accuracy of the 
two subscales separately, but strongly suggest the use of the HADS total score (HADS-Tot) [8-11].  
On these bases, the general aim of this study is to provide clinicians with the optimal HADS  
cut-off to identify depressed patients. We thus investigated the concurrent validity of the HADS-
Tot with a clinician-rated scale, assessing depression in two groups of cardiac hospitalized 
patients - Acute Coronary Syndrome (ACS) and chronic Coronary Artery Disease (CAD). 
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2. Methods 
2.1. Patients and procedure 
The study was proposed to all consecutive patients hospitalized in the Cardiology Unit of the 
“Città della Salute e della Scienza” Hospital of Turin. All patients who gave their written 
informed consent and completed the HADS had a clinical interview with an expert 
psychologist who filled in the Montgomery-Asberg Depression Rating Scale (MADRS).  
From a pool of 1049 inpatients who completed the HADS, the data of 357 patients with ACS 
and 260 with chronic CAD were analysed. 
2.2. Measures 
The MADRS, a semi-structured clinical interview rated by an expert clinical 
psychologist/psychiatrist, is one of the gold-standard clinician-rated diagnostic tools [12]. 
Following the widely-accepted recommendations, the cut-off value of 11 was used to tally a 
patient as depressed (≥11) or not (<11) [12,13].  
The HADS is a brief self-rating instrument composed of 14 items rated between 0-3,  
widely used in physically ill patients [14,15]. It evaluates the presence of depressive and 
anxiety symptoms. According to the more recent methodological studies published on the 
matter, the total score was used as an index of psychological distress [9]. 
2.3. Statistical analyses 
All statistical analyses were performed using the Statistical Package for Social Science  
(SPSS-23). A Receiver Operating Characteristics (ROC) curve was plotted separately for ACS 
and CAD patients, using the results of the MADRS as the criterion.  
Positive (PPV) and negative (NPV) predictive values, accuracy and distance (d) to the optimal 
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(0,1) point were computed for different cut-off scores. To determine the optimal cut-off score, 
both the “point of curve closest to the (0,1)” criteria (d value) and visual assessment of the 
score combining maximal sensitivity with optimal specificity were considered. 
 
3. Results 
Table 1 shows the demographic characteristics of the two groups. ACS and CAD patients 
reported a mean (SD) HADS-Tot raw score of 10.7 (7.5) and 11.8 (7.4) respectively, with 19% 
(68) of patients in the former group and 29.6% (77) in the latter showing clinically relevant 
depressive symptoms according to the MADRS (Table 1).  
The ROC curve analyses showed an excellent/very good accuracy of the HADS-Tot in both 
groups, with an area under the curve (AUC) of .911 for the ACS and .893 for the CAD group 
(Table 2). Between the possible cut-off values with the lowest d values, visual inspection of  
the data revealed that the cut-off of 14 showed the best compromise between high sensitivity and 
good specificity in both ACS and CAD patients, with high NPVs (95.5% for ACS and 92.4% 
for CAD) (Table 2). 
 
4. Discussion 
Depressive symptoms have a negative role in CVD, increasing the risk of new cardiac events 
and negative outcomes, and worsening patients’ quality of life [2]. Indeed, post-myocardial 
infarction (MI) depression is associated with a 1.5- to 2.7-fold increased risk for both post-MI 
mortality and new cardiac events [16]. Despite the negative effects of depression on cardiac 
patients, its assessment is still underused, especially in the Italian cardiology hospital setting.  
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The opportunity to screen for and treat depression in hospitalized cardiac patients should not be 
missed, also because the risk of mortality or new cardiovascular events in cardiac patients with 
depression increases mainly in the first two years after the original cardiac event [17].  
Accurate assessment of depressive disorders with a semi-structured interview, such as the 
Structured Clinical Interview for DSM disorders (SCID-I) or the MADRS, would be costly for 
the healthcare system in terms of both time (more than 30 minutes) and money, and may not 
suit the routine of the hospital setting. This is why clinical guidelines [5,18] usually recommend 
a two-step procedure: first, screening with a self-report scale; then, evaluation with a more 
accurate assessment (i.e. MADRS) of positive patients. So it is crucial to choose a rapid  
self-administered tool allowing easy but accurate first-step screening, in order to accurately 
identify those patients requiring further psychological assessment. The HADS is a clinical tool 
specifically developed to assess depressive and anxiety symptoms in physically ill patients [19]. 
It has the advantage of being an easy and rapid self-report instrument (no more than 5 minutes) 
that can be administered during admission or in a waiting room and takes no longer than a 
minute to be scored by the clinician. The HADS screening procedure could easily be inserted 
into the hospital routine, allowing the screening of all patients and reducing drop-out, since 
discharged patients are often unwilling to return for further scheduled medical appointments. 
To this aim, recent evidence suggests using the HADS total score, but not the two subscales score 
separately [8-11]. This indication has both a clinical and a methodological rationale. Clinically, 
depressive disorders are often the result of not only depressive but also anxiety symptoms, 
which frequently overlap. Indeed, symptoms of anxiety and depression could both be 
considered parts of that multidimensional continuum called psychological distress,  
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which ranges from normal feelings of vulnerability, sadness and fears to problems that could 
become disabling, such as depressive disorders. A valid first-step screening tool should 
therefore account for the overall psychological distress [11]. 
From a methodological standpoint, recent confirmatory factor analysis (CFA) suggests that the 
HADS is saturated by a single general distress factor (explaining over 70% of the variance), 
with the two subscales showing weak item loadings separately [9,10]. These data provide 
psychometric evidence against the internal consistency of the two subscales in favor of the 
reliability of the HADS-Tot [9,10]. What is more, a recent study shows that the HADS-Tot is a 
valid measure and that it is predictive of future symptoms of distress, healthcare costs and 
quality of life in a CHD population [11]. 
The data of the present study show that, compared to the MADRS, the HADS-Tot has good 
reliability and accuracy for ACS and CAD patients. In both groups, 14 is the cut-off with the 
best psychometric properties to screen those patients with clinically relevant levels of 
psychological distress who should be submitted to a more in-depth assessment for depression. 
This cut-off provides not only high sensitivity, but also high specificity, with about 4 out of 5 
patients correctly classified, as shown by the accuracy values. What is more, this cut-off shows 
high NPVs (95% for ACS and 92% for CAD), meaning that 9 out of 10 patients who, 
according to the HADS-Tot did not present a clinically relevant level of psychological distress 
and therefore did not require further psychological investigation, were correctly identified  
(i.e. they really were non-depressed, according to the MADRS). Clinically, these screening 
procedures allow the healthcare provider to correctly reduce the number of patients requiring 
more in-depth depression assessment procedures (clinical interviews) with a considerable 
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reduction in time and money spent. What is more, using a unique cut-off for both pathologies 
could increase the practicality of this tool, allowing an immediate scoring of the HADS, 
independently of the cardiac diagnosis. 
In conclusion, the data of the present study suggest that, using a cut-off value of 14, the HADS 
could be considered a good first-step screening tool in order to identify CAD and ACS 
inpatients with a relevant level of psychological distress, who risk developing depressive 
disorders, and thus require a deeper second-step assessment.  
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Table 1. Demographic and clinical characteristics of the 617 CVD patients. 
Variable ACS (N=357) CAD (N=260) 
Age (Mean (SD)) 67.3 (11.4) 69 (9.8) 
Sex (N (%))   
Male 269 (75.4) 190 (73.1) 
Female 88 (24.6) 70 (26.9) 
Educational level (Mean (SD)) 9.6 (4.4) 9.7 (4.1) 
Marital status (N (%))   
Single 25 (7) 18 (6.9) 
Married/cohabiting 264 (74.4) 200 (76.9) 
Divorced 21 (5.9) 21 (8.1) 
Widowed 45 (12.7) 21 (8.1) 
Employment status (N (%))   
Employed 97 (29.3) 50 (19.9) 
Unemployed/homemaker 22 (6.7) 22 (8.8) 
Retired 212 (64) 179 (71.3) 
   
MADRS 6.8 (5.9) 8.6 (6.2) 
Above cut-off (Cases) (N (%)) 68 (19) 77 (29.6) 
HADS-Tot 10.7 (7.5) 11.8 (7.4) 
HADS-D 4.9 (4.2) 5.7 (4.1) 
HADS-A 5.8 (4.2) 6.2 (4.1) 
ACS: Acute Coronary Syndrome; CAD: chronic Coronary Artery Disease;  
MADRS: Montgomery-Asberg Depression Rating Scale; 
HADS-Tot: Hospital Anxiety and Depression Scale – total score; 
HADS-D/-A: Hospital Anxiety and Depression Scale – depression/anxiety subscale.
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